SCM
UTHR icon

Silverarc Capital Management’s United Therapeutics UTHR Stock Holding History

Silverarc Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-59,900
Closed -$25.1M – 96
2025
Q3 		$25.1M Buy
+59,900
New +$20.1M 3.39% 11

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

Silverarc Capital Management's UTHR Position: Q1 2024 in Review

Silverarc Capital Management sold out of United Therapeutics (UTHR) in Q1 2024, closing a stake of 16,360 shares — an estimated $3.6M sold.

Silverarc Capital Management first reported a position in UTHR in Q4 2020 and held it in 13 quarters. The position peaked at $7.1M in Q3 2023. 525 funds tracked by Wall St. Rank hold UTHR as of Q1 2024.

  • Silverarc Capital Management reported no remaining United Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Silverarc Capital Management sold 16,360 United Therapeutics shares in Q1 2024, an estimated $3.6M.
  • Silverarc Capital Management first reported a position in United Therapeutics in Q4 2020 and held it in 13 quarters.
  • Silverarc Capital Management's United Therapeutics position peaked at $7.1M in Q3 2023.
  • 525 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2024.

Based on Silverarc Capital Management's 13F filing for Q1 2024, filed 15 May 2024.